Nothing said here yet.
to join the conversation.
| Chan Phillip P.Chief Executive Officer | Buy | 3,774 | $22.6K | Tue, Sep 15 |
| Sobel Alan D.Director | Buy | 1,900 | $11.6K | Tue, Sep 15 |
| Sobel Alan D.Director | Buy | 500 | $3.0K | Tue, Sep 15 |
| Sobel Alan D.Director | Buy | 100 | $601 | Tue, Sep 15 |
| Capponi VincentPresident and COO | Buy | 1,800 | $10.9K | Mon, Sep 14 |
| Capponi VincentPresident and COO | Buy | 273 | $1.6K | Mon, Sep 14 |
| Chan Phillip P.Chief Executive Officer | Buy | 200,000 | $70.0K | Fri, Sep 4 |
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the…
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock").
By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT New Findings Presented at European Society of Cardiology (ESC) Congress 2026 On September 2, 2026, the CytoSorbents (NASDAQ: CTSO) announced an independent new patient-level matched analysis of…
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse…
By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT 2nd Quarter 2026 Financial Results On August 6, 2026, CytoSorbents (NASDAQ: CTSO) released 2 nd quarter financial and operating results.
Cash burn improved as company pursues FDA approval for DrugSorb-ATR device.
CytoSorbents Corp (CTSO) slashes cash burn to $200K, boosts gross margins to 73%, and advances DrugSorb ATR and Hemodefen BGA regulatory pathways despite STAR-T trial setback.